Abstract
Gastrinomas are functional endocrine duodenopancreatic tumors and are responsible for the Zollinger-Ellison-syndrome (ZES). Although most gastrinomas grow slowly, 60–90% are malignant [1]. The natural course of sporadic ZES is more aggressive than of MEN1ZES with 15 years survival rates of 70-80 and 100% [2]. Patients with metastatic sporadic gastrinoma have 5-year survival rates of only 20– 38%. Surgery is the only way to cure ZES. In this editorial the surgical management of sporadic and MEN-1 associated gastrinomas will be discussed.
Highlights
Gastrinomas are functional endocrine duodenopancreatic tumors and are responsible for the Zollinger-Ellison-syndrome (ZES)
The 15-year disease-related survival was 98% after surgery and 74% after medical treatment (P< 0.001). These results demonstrate that routine surgical exploration increases survival in patients with ZES by increasing disease-related survival and reducing the rate of advanced disease [3]
Routine surgical exploration should be performed in all patients with sporadic gastrinomas without evidence of diffuse hepatic metastases or concurrent illness limiting life expectancy
Summary
Gastrinomas are functional endocrine duodenopancreatic tumors and are responsible for the Zollinger-Ellison-syndrome (ZES). Most gastrinomas grow slowly, 60–90% are malignant [1]. The natural course of sporadic ZES is more aggressive than of MEN1ZES with 15 years survival rates of 70-80 and 100% [2]. Patients with metastatic sporadic gastrinoma have 5-year survival rates of only 20– 38%. Surgery is the only way to cure ZES. In this editorial the surgical management of sporadic and MEN-1 associated gastrinomas will be discussed
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
